Real-World Adherence and Persistence to Glucagon-Like Peptide-1 Receptor Agonists Among Non-Diabetic Obese Commercially Insured Adults 

Authors:​​ A.M. Wilson, PharmD; B.D. Hunter, MS; K. Brown-Gentry, MS; K. Lockhart, MS; J. Scripture, PhD, MS​ 
This study measured adherence and persistence to GLP-1 therapy in a real-world cohort of commercially insured non-diabetic members newly initiating certain drugs to treat obesity. 

Real-World First Year Cost-Effectiveness Assessment of Glucagon-Like Peptide-1 Agonists to Treat Non-Diabetes Obesity 
Authors:​​ A.M. Wilson, PharmD; B.D. Hunter, MS; K. Brown-Gentry, MS; K. Lockhart, MS; J. Scripture, PhD, MS​ 
An assessment describing the changes in total cost of care a year before and after GLP-1 initiation treatment among obese commercially insured members without diabetes compared to a concurrent matched control group. 

Obesity with Preexisting Cardiovascular Disease without Diabetes: Current Glucagon-Like Peptide-1 (GLP-1) Agonist Treatment Prevalence Among 16 Million Commercially Insured Members 
Authors:​​ A.M. Wilson, PharmD; B.D. Hunter, MS; K. Brown-Gentry, MS; K. Lockhart, MS; J. Scripture, PhD, MS​ 
This study identified GLP-1 treatment prevalence and future-use potential among commercially insured members with obesity and cardiovascular disease, without DM, via integrated pharmacy and medical claims data. 

Medically Integrated Dispensing of Oral Oncolytics: Real-World Cost of Care Comparison to Traditional Dispensing   
Authors:​​ A.M. Wilson, PharmD; B.D. Hunter, MS; K. Brown-Gentry, MS; K. Lockhart, MS; J. Scripture, PhD, MS​ 
This study compared six-month pre/post cost of care differences between integrated and non-integrated dispensing channels among commercially insured members initiating OO therapy. 

Medication Nonadherence Social Determinants of Health Risk Score: Development and Use 
Authors:​​ A.M. Wilson, PharmD; B.D. Hunter, MS; K. Brown-Gentry, MS; K. Lockhart, MS; J. Scripture, PhD, MS​ 
Created to support medication management and improve adherence by developing a Medicare member specific SDOH-related medication nonadherence risk score prioritization model.

Promoting Generic Multiple Sclerosis Drug Utilization and Drug Cost Savings with a Managed Care Pharmacist Outreach Program 
Authors:​​ A.M. Wilson, PharmD; B.D. Hunter, MS; K. Brown-Gentry, MS; K. Lockhart, MS; J. Scripture, PhD, MS​ 
This study assessed per member per month (PMPM) costs for MS brand name drugs with generic alternatives among commercially insured members, evaluated a managed care pharmacist (MCP) intervention program’s effectiveness in steering brand name MS drug utilizers to the equivalent generic, and described associated drug cost savings. 

Retrospective Claims Analysis of Opioid Prescribing Patterns: Single and Combination Agents for Acute Pain and Subsequent Conversion to Chronic Opioid Usage Among Commercial Members 
Authors:​​ A.M. Wilson, PharmD; B.D. Hunter, MS; K. Brown-Gentry, MS; K. Lockhart, MS; J. Scripture, PhD, MS​ 
This study assessed the impact of initiation with a combination agent (CA) vs. a single agent (SA) in opioid naïve members with acute pain and subsequent conversion to opioid dependence. 

Real-World Utilization Differences Between SGLT2 Inhibitors and GLP-1 Receptor Agonists Post Metformin Monotherapy
Authors:​​ A.M. Wilson, PharmD; B.D. Hunter, MS; K. Brown-Gentry, MS; K. Lockhart, MS; J. Scripture, PhD, MS​ 
This study examined the relationship between proportion of days covered (PDC), adherence, persistence and time to add or switch therapies over 18 months post SGLT2 vs. GLP-1 initiation. 

All brand names are property of their respective owners.